|
Sam Eletr, PhD currently serves as the interim CEO of Population Genetics, Ltd., a seed stage company based in the UK. Also, he currently serves as a Director of Third Wave Technologies (a NASDAQ-listed, DNA-based, diagnostic products company), of Faust Pharmaceuticals, a biopharmaceutical company based in Strasbourg, France and of SpinX Technologies, a micro-fluidics company based in Geneva, Switzerland. Dr. Eletr also served as a Director of i-STAT, a point-of-care diagnostics company, from 2001 until its acquisition by Abbott Laboratories in December 2003 and as a Director of Solexa, Ltd, a genomics company based in Cambridge, England, from 2002 until July 2004. From 1992 to 1999, Dr. Eletr served as Chairman of the Board of Lynx Therapeutics, a publicly traded genomics company. In late 1979, he co-founded Applied Biosystems, Inc. (now the Applied Biosystems Group of Applera Corporation), a developer and manufacturer of protein and DNA synthesis and sequencing instruments and reagents, where he served as Chairman and CEO from its founding until 1987. Prior to co-founding Applied Biosystems, he was Manager of an Analytical and Medical Instruments Group at the Hewlett-Packard corporate research laboratories in Palo Alto. Dr. Eletr obtained an MA in Physics and a PhD in Biophysical Chemistry from the University of California at Berkeley. Prior to his MA, he studied Electrical Engineering at the Polytechnic Institute in Grenoble, France. | 